Skip to main content
PMC home page
Journal of Assisted Reproduction and Genetics logoLink to Journal of Assisted Reproduction and Genetics
. 2000 Aug;17(7):357–373. doi: 10.1023/A:1009465324197

Evaluation and Treatment of Low Responders in Assisted Reproductive Technology: A Challenge to Meet

Sozos J Fasouliotis 1, Alex Simon 1, Neri Laufer 1
PMCID: PMC3489420  PMID: 11077616

Abstract

Purpose: To investigate the various methods of evaluationand treatment of patients with a low response to controlledovarian hyperstimulation in assisted reproductive technologies (ART). Methods: Review and analysis of relevant studies publishedin the last decade, identified through the literature and Medlinesearches. Results: While a universally accepted definition for lowresponders is still lacking, these patients are reported torepresent about 10% of the ART population. Several ovarianreserve screening techniques have been proposed; however,currently the best-characterized and most sensitive screeningtools available are the basal day 3 serum follicle-stimulatinghormone level and the clomiphene citrate challenge test.When abnormal, these tests allow physicians to counselpatients that their prognosis for conception is poor. Althoughthe presence of a normal result does indicate better long-termchances for conception, an age-related decline in fecundityremains and patient age should still be considered whencounseling patients with normal screening results. Severalstimulation protocols have been applied in the low-responsegroup with varying success. Recent studies show that theuse of a minidose gonadotropin-releasing hormone-agonistprotocol may result in significantly decreased cycle cancellationsas well as increased clinical and ongoing pregnancies,and thus is proposed as a first-line therapy. Studies evaluatingsupplementary forms of treatment to the ovulation inductionregimen show improved outcome when pretreating withoral contraceptives, whereas there seems to be no benefitfrom cotreatment with growth hormone or glucocorticoids.Blastocyst culture and transfer and assisted hatching in lowresponders are still under evaluation, whereas natural cyclein vitro fertilization may be used in cases of repeated failuresas a last option before resorting to oocyte donation or adoption.Future possible forms of treatment like in vitro maturationof immature human oocytes, cytoplasm, and nucleartransfer currently are experimental in nature and their efficacyhas still to be proven.Conclusions: The evaluation and treatment of low respondersin ART remains a challenge. Understanding of the underlyingetiology and pathophysiology of this disorder may helpthe clinician to approach it successfully.

Keywords: Assisted reproductive technologies; low responders; ovarian response, ovulation induction

Full Text

The Full Text of this article is available as a PDF (215.1 KB).

REFERENCES

  • 1.Pellicer A, Lightman A, Diamond MP, Russell JB, DeCherney AH. Outcome of in vitro fertilization in women with low response to ovarian stimulation. Fertil Steril. 1987;47:812–815. doi: 10.1016/s0015-0282(16)59170-5. [DOI] [PubMed] [Google Scholar]
  • 2.Laufer N, Navot D. Human in vitro fertilization. In: DeCherney AH, editor. Reproductive Failure. 1st ed. New York: Churchill Livingstone; 1986. pp. 219–246. [Google Scholar]
  • 3.Garcia J, Jones GS, Acosta AA, Wright GL., Jr Human menopausal gonadotropin/human chorionic gonadotropin follicular maturation for oocyte aspiration: phase II, 1981. Fertil Steril. 1983;39:174–179. doi: 10.1016/s0015-0282(16)46815-9. [DOI] [PubMed] [Google Scholar]
  • 4.Hanoch J, Lavy Y, Holzer H, Hurwitz A, Simon A, Revel A, Laufer N. Young low responders protected from untoward effects of reduced ovarian response. Fertil Steril. 1998;69:1001–1004. doi: 10.1016/s0015-0282(98)00079-x. [DOI] [PubMed] [Google Scholar]
  • 5.Muasher SJ. Controversies in assisted reproduction: Treatment of low responders. J Assist Reprod Genet. 1993;10:112–114. doi: 10.1007/BF01207730. [DOI] [PubMed] [Google Scholar]
  • 6.Jacobs SL, Metzger DA, Dodson WC, Haney AF. Effect of age on response to human menopausal gonadotropin stimulation. J Clin Endocrinol Metab. 1990;71:1525–1530. doi: 10.1210/jcem-71-6-1525. [DOI] [PubMed] [Google Scholar]
  • 7.Cameron IT, O'Shea FC, Rolland JM, Hughes EG, De Kretser DM, Healy DL. Occult ovarian failure:Asyndrome of infertil-ity, regular menses, and elevated follicle-stimulating hormone concentrations. J Clin Endocrinol Metab. 1988;67:1190–1194. doi: 10.1210/jcem-67-6-1190. [DOI] [PubMed] [Google Scholar]
  • 8.Pellicer A, Ballester MJ, Serrano MD, Mir A, Serra-Serra V, Remohi J, Bonilla-Musoles MF. Aetiological factors involved in the low response to gonadotrophins in infertile women with normal basal serum follicle stimulating hormone levels. Hum Reprod. 1994;9:806–811. doi: 10.1093/oxfordjournals.humrep.a138600. [DOI] [PubMed] [Google Scholar]
  • 9.Wallach EE. Pitfalls in evaluating ovarian reserve. Fertil Steril. 1995;63:12–14. doi: 10.1016/s0015-0282(16)57288-4. [DOI] [PubMed] [Google Scholar]
  • 10.Federation CECOS, Schwartz D, Mayaux MJ. Female fecunin dity as a function of age: Results of an artificial insemination in 2193 nulliparous women with azoospermic husbands. N Engl J Med. 1982;306:404–406. doi: 10.1056/NEJM198202183060706. [DOI] [PubMed] [Google Scholar]
  • 11.Templeton A, Morris JK, Parslow W. Factors that affect outcome of in-vitro fertilization treatment. Lancet. 1996;348:1402–1406. doi: 10.1016/S0140-6736(96)05291-9. [DOI] [PubMed] [Google Scholar]
  • 12.Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod. 1992;7:1342–1346. doi: 10.1093/oxfordjournals.humrep.a137570. [DOI] [PubMed] [Google Scholar]
  • 13.Lass A, Croucher C, Duffy S, Dawson K, Margara R, Winston RM. One thousand initiated cycles of in vitro fertilization in women > or 5 40 years of age. Fertil Steril. 1998;70:1030–1034. doi: 10.1016/s0015-0282(98)00353-7. [DOI] [PubMed] [Google Scholar]
  • 14.1998 Annual report and accounts. London, England: HFEA; 1998. [Google Scholar]
  • 15.Society for Assisted Reproductive Technology, the American Society for Reproductive Medicine: Assisted reproductive technology in the United States 1996 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry. Fertil Steril. 1999;71:798–807. doi: 10.1016/s0015-0282(99)00124-7. [DOI] [PubMed] [Google Scholar]
  • 16.Toner JP, Philput CB, Jones GS, Muasher SJ. Basal folliclestimulating hormone level is a better predictor of in vitro fertilization performance than age. Fertil Steril. 1991;55:784–791. doi: 10.1016/s0015-0282(16)54249-6. [DOI] [PubMed] [Google Scholar]
  • 17.Scott RT, Toner JP, Muasher SJ, Oehninger S, Robinson S, Rosenwaks Z. Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril. 1989;51:651–654. doi: 10.1016/s0015-0282(16)60615-5. [DOI] [PubMed] [Google Scholar]
  • 18.Lenton E, Sexton L, Lee S, Cooke I. Progressive changes in LH and FSH and LH:FSH ratio in women throughout reproductive life. Maturitas. 1988;10:35–43. doi: 10.1016/0378-5122(88)90129-6. [DOI] [PubMed] [Google Scholar]
  • 19.Mukherjee T, Copperman AB, Lapinski R, Sandler B, Bustillo M, Grunfeld L. An elevated day three follicle-stimulating hormone:luteinizing hormone ratio (FSH:LH) in the presence of a normal day 3 FSH predicts a poor response to controlled ovarian hyperstimulation. Fertil Steril. 1996;65:588–593. doi: 10.1016/s0015-0282(16)58159-x. [DOI] [PubMed] [Google Scholar]
  • 20.Smotrich DB, Widra EA, Gindoff PR, Levy MJ, Hall JL, Stillman RJ. Prognostic value of day 3 estradiol on in vitro fertilization outcome. Fertil Steril. 1995;64:1136–1140. [PubMed] [Google Scholar]
  • 21.Licciardi FL, Liu HC, Rosenwaks Z. Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization. Fertil Steril. 1995;64:991–994. doi: 10.1016/s0015-0282(16)57916-3. [DOI] [PubMed] [Google Scholar]
  • 22.Navot D, Rosenwaks Z, Margalioth EJ. Prognostic assessment of female fecundity. Lancet. 1989;2:645–647. doi: 10.1016/s0140-6736(87)92439-1. [DOI] [PubMed] [Google Scholar]
  • 23.Tanbo T, Dale PO, Lunde O, Norman N, Abyholm T. Prediction of response to controlled ovarian hyperstimulation: a gonadocomparison of basal and clomiphene citrate-stimulated folli-cle-stimulating hormone levels. Fertil Steril. 1992;57:819–824. doi: 10.1016/s0015-0282(16)54965-6. [DOI] [PubMed] [Google Scholar]
  • 24.Loumaye E, Billion JM, Mine JM, Psalti I, Pensis M, Thomas K. Prediction of individual response to controlled ovarian hyperstimulation by means of a clomiphene citrate challenge test. Fertil Steril. 1990;53:295–301. doi: 10.1016/s0015-0282(16)53284-1. [DOI] [PubMed] [Google Scholar]
  • 25.Tanbo T, Dale PO, Abyholm T, Stokke KT. Follicle-stimulating hormone as a prognostic indicator in clomiphene citrate/ human menopausal gonadotrophin-stimulated cycles for in vitro fertilization. Hum Reprod. 1989;6:647–650. doi: 10.1093/oxfordjournals.humrep.a136959. [DOI] [PubMed] [Google Scholar]
  • 26.Winslow KL, Toner JP, Brzyski RG, Oehninger SC, Acosta AA, Muasher SJ. The gonadotropin-releasing hormone agonist stimulation test-A sensitive predictor of performance in the flare-up in vitro fertilization cycle. Fertil Steril. 1991;56:711–717. doi: 10.1016/s0015-0282(16)54604-4. [DOI] [PubMed] [Google Scholar]
  • 27.Scott RT, Jr, Hofmann GE. Prognostic assessment of ovarian reserve. Fertil Steril. 1995;63:1–11. [PubMed] [Google Scholar]
  • 28.Society for Assisted Reproductive Technology, the American Fertility Society: Assisted reproductive technology in the United StatesCanada 1992 results generated from the American Fertility Society/Society for Assisted Reproductive Technology Registry. Fertil Steril. 1994;62:1121–1128. doi: 10.1016/s0015-0282(16)57172-6. [DOI] [PubMed] [Google Scholar]
  • 29.Zaidi J, Barber J, Kyei-Mensah A, Bekir J, Campbell S, Tan SL. Relationship of ovarian stromal blood flow at the baseline ultrasound scan to subsequent follicular response in an in vitro fertilization program. Obstet Gynecol. 1996;88:779–784. doi: 10.1016/0029-7844(96)00316-X. [DOI] [PubMed] [Google Scholar]
  • 30.Oyesanya O, Parsons JH, Collins WP, Campbell S. Prediction of oocyte recovery rate by transvaginal ultrasonography and color Doppler imaging before human chorionic gonadotropin administration in in vitro fertilization cycles. Fertil Steril. 1996;65:806–809. doi: 10.1016/s0015-0282(16)58218-1. [DOI] [PubMed] [Google Scholar]
  • 31.Brown JM, Schwartz LB, Olive D, Lange R, Laufer N, Taylor KJW. Evaluation of Doppler ultrasonography as a means of monitoring in vitro fertilization and embryo transfer cycles: Preliminary results and findings. J Ultrasound Med. 1997;16:411–416. doi: 10.7863/jum.1997.16.6.411. [DOI] [PubMed] [Google Scholar]
  • 32.Weiner Z, Thaler I, Levron J, Lewit N, Itskowitz-Eldor J. Assessment of ovarian and uterine blood flow by transvaginal color Doppler in ovarian-stimulated women: Correlation with the number of follicles and steroid hormone levels. Fertil Steril. 1993;59:743–749. doi: 10.1016/s0015-0282(16)55853-1. [DOI] [PubMed] [Google Scholar]
  • 33.Chang MY, Chiang CH, Hsieh TT, Soong YK, Hsu KH. Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertil Steril. 1998;69:505–510. doi: 10.1016/s0015-0282(97)00557-8. [DOI] [PubMed] [Google Scholar]
  • 34.Bonilla-Musoles F, Raga F, Osborne NG. Three-dimensional ultrasound evaluation of ovarian masses. Gynecol Oncol. 1995;59:129–135. doi: 10.1006/gyno.1995.1279. [DOI] [PubMed] [Google Scholar]
  • 35.Bonilla-Musoles F, Raga F, Osborne NG, Pellicer A, Blanes J. Use of three-dimensional ultrasound in reproductive medicine. Assist Reprod Rev. 1995;5:170–188. [Google Scholar]
  • 36.Pellicer A, Ardiles G, Neuspiller F, Remohi J, Simon C, Bonilla-Musoles F. Evaluation of the ovarian reserve in young low responders with normal basal levels of follicle-stimulating hormone using three-dimensional ultrasonography. Fertil Steril. 1998;70:671–675. doi: 10.1016/s0015-0282(98)00268-4. [DOI] [PubMed] [Google Scholar]
  • 37.Agnani G, Joanne CH, Oudghiri F, Benoit S, Gay C, Roux CH. Ultrasound evaluation of the follicular pool in the detection of poor responders. Hum Reprod. 1997;12(suppl.1):216. [Google Scholar]
  • 38.Tummon IS, Daniel SAJ, Kaplan BR, Nisker JA, Yuzpe AA. Randomized, prospective comparison of luteal leuprolide acetion tate and gonadotropins versus clomiphene citrate and gonadocomparison tropins in 408 first cycles of in vitro fertilization. Fertil Steril. 1992;58:563–568. [PubMed] [Google Scholar]
  • 39.Dor J, Ben-Shlomo I, Levran D, Rudak E, Yunish M, Mashiach S. The relative success of gonadotropin-releasing hormone analogue, clomiphene citrate, and gonadotropin in 1,099 cycles of in vitro fertilization. Fertil Steril. 1992;58:986–990. doi: 10.1016/s0015-0282(16)55447-8. [DOI] [PubMed] [Google Scholar]
  • 40.Benadiva CA, Davis O, Kligman I, Liu HC, Rosenwaks Z. Clomiphene citrate and hMG: An alternative stimulation protocol for selected failed in vitro fertilization patients. J Assist Reprod Genet. 1995;12:8–12. doi: 10.1007/BF02214121. [DOI] [PubMed] [Google Scholar]
  • 41.Ben-Rafael Z, Feldberg D. The poor-responder patient in an in vitro fertilization-embryo transfer program. J Assist Reprod Genet. 1993;10:118–120. doi: 10.1007/BF01207732. [DOI] [PubMed] [Google Scholar]
  • 42.Pantos C, Thornton SJ, Speirs AL, Johnston I. Increasing the human menopausal gonadotropin dose-Does the response really improve? Fertil Steril. 1990;53:436–439. doi: 10.1016/s0015-0282(16)53337-8. [DOI] [PubMed] [Google Scholar]
  • 43.Awonuga AO, Nabi A. In vitro fertilization with low-dose clomiphene citrate stimulation in women who respond poorly to superovulation. J Assist Reprod Genet. 1997;14:503–507. doi: 10.1023/A:1021171225322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Scott RT. Evaluation and treatment of low responders. Semin Reprod Endocrinol. 1996;14:317–337. doi: 10.1055/s-2008-1067977. [DOI] [PubMed] [Google Scholar]
  • 45.Laufer N, DeCherney AH, Haseltine FP, Dumolin JC. The use of high-dose human menopausal gonadotropin in an in vitro fertilization program. Fertil Steril. 1982;38:734–741. doi: 10.1016/s0015-0282(16)47472-8. [DOI] [PubMed] [Google Scholar]
  • 46.Jones HW, Jr, Jones GS, Andrews MC, Acosta A, Bundren C, Garcia J, Sandow B, Veeck L, Wilkes C, Witmyer J, Wortham JE, Wright G. The program for in vitro fertilization at Norfolk. Fertil Steril. 1982;38:14–21. [PubMed] [Google Scholar]
  • 47.Hofmann GE, Toner JP, Muasher SJ, Jones GS. High-dose follicle-stimulating (FSH) ovarian stimulation in low responder patients for in vitro fertilization. J In Vitro Fertil Embryo Transfer. 1989;6:285–289. doi: 10.1007/BF01139183. [DOI] [PubMed] [Google Scholar]
  • 48.McKenna KM, Foster P, McBain J, Martin M, Johnston W. Combined treatment with gonadotropin releasing hormone agonist and gonadotropins in poor responders to hyperstimula-tion for in vitro fertilization (IVF): Clinical and endocrine results. Aust NZ J Obstet Gynecol. 1989;29:428–432. doi: 10.1111/j.1479-828x.1989.tb01782.x. [DOI] [PubMed] [Google Scholar]
  • 49.Karande VC, Jones GS, Veeck LL, Muasher SJ. High-dose follicle stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low-responder patients. Fertil Steril. 1990;53:486–489. doi: 10.1016/s0015-0282(16)53345-7. [DOI] [PubMed] [Google Scholar]
  • 50.Stadmauer L, Ditkoff EC, Session D, Kelly A. High dosages of gonadotropins are associated with poor pregnancy out-comes after in vitro fertilization-embryo transfer. Fertil Steril. 1994;61:1058–1064. doi: 10.1016/s0015-0282(16)56756-9. [DOI] [PubMed] [Google Scholar]
  • 51.Land JA, Yarmolinskaya MI, Dumoulin JCM, Evers JLH. High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization out-come. Fertil Steril. 1996;65:961–965. doi: 10.1016/s0015-0282(16)58269-7. [DOI] [PubMed] [Google Scholar]
  • 52.Rombauts L, Suikkari AM, MacLachian V, Trounson AO, Healy DL. Recruitment of follicles by recombinant human follicle-stimulating hormone commencing in the luteal phase of the ovarian cycle. Fertil Steril. 1998;69:665–669. doi: 10.1016/s0015-0282(98)00018-1. [DOI] [PubMed] [Google Scholar]
  • 53.Frydman R, Parneix I, Belaisch-Allart J, Forman R, Hazout A, Fernandez H, Testart J. LHRH agonist in IVF: Different methods of utilization and comparison with previous ovulation stimulation treatments. Hum Reprod. 1988;3:559–561. doi: 10.1093/oxfordjournals.humrep.a136744. [DOI] [PubMed] [Google Scholar]
  • 54.Remorgida V, Anserini P, Croce S, Costa M, Ferraiolo A, Centonze A, Gaggero G, Capitanio GL. The duration of pituitary suppression by means of intranasal gonadotropin hormone-releasing analogue administration does not influence the ovarian response to gonadotropin stimulation and success rate in a gamete intrafallopian transfer (GIFT) program. J In Vitro Fertil Embryo Transf. 1989;6:76–80. doi: 10.1007/BF01130730. [DOI] [PubMed] [Google Scholar]
  • 55.Smitz J, Ron-El R, Tarlatzis BC. The use of gonadotropin releasing hormone agonists for in vitro fertilization and other assisted procreation techniques: Experience from three centers. Hum Reprod. 1992;7(suppl.1):49–66. doi: 10.1093/humrep/7.suppl_1.49. [DOI] [PubMed] [Google Scholar]
  • 56.Toth TL, Awwas JT, Veeck LL, Jones HW, Jr, Muasher SJ. Suppression and flare regimens of gonadotropin-releasing hormone agonist: Use in women with different basal gonadotropin values in an in vitro fertilization program. J Reprod Med. 1996;41:321–326. [PubMed] [Google Scholar]
  • 57.Jenkins JM, Davies DW, Devonport H, Anthony FW, Gadd SC, Watson RH, Masson GM. Comparison of “poor” responders with “good” responders using a standard buserelin/human menopausal gonadotrophin regime for in-vitro fertilization. Hum Reprod. 1991;7:918–921. doi: 10.1093/oxfordjournals.humrep.a137459. [DOI] [PubMed] [Google Scholar]
  • 58.Tasdemir M, Tasdemir I, Kodama H, Fukuda J, Tanaka T. Short protocol of gonadotropin releasing hormone agonist administration gave better results in long protocol poor responders in IVF-ET. J Obstet Gynaecol Res. 1996;22:73–77. doi: 10.1111/j.1447-0756.1996.tb00940.x. [DOI] [PubMed] [Google Scholar]
  • 59.Olivennes F, Righini C, Fanchin R, Torrisi C, Hazout A, Glissant M, Fernandez H, Frydman H. A protocol using a low dose of gonadotropin-releasing hormone agonist might be the best protocol for patients with high follicle stimulating hormone concentrations on day 3. Hum Reprod. 1996;11:1169–1172. doi: 10.1093/oxfordjournals.humrep.a019348. [DOI] [PubMed] [Google Scholar]
  • 60.Padilla SL, Dugan K, Maruschak V, Shaika S, Smith RD. Use of the flare-up protocol with high dose human follicle stimulating hormone and human menopausal gonadotropins for in vitro fertilization in poor responders. Fertil Steril. 1996;65:796–799. doi: 10.1016/s0015-0282(16)58216-8. [DOI] [PubMed] [Google Scholar]
  • 61.Yang JH, Wu MY, Chao KH, Chen SU, Ho HN, Yang YS. Long GnRH-agonist protocol in an IVF program: Is it appropriate for women with normal FSH levels and high FSH/LH ratios? J Reprod Med. 1997;42:663–668. [PubMed] [Google Scholar]
  • 62.Gelety TJ, Pearlstone AC, Surrey ES. Short-term endocrine responses to gonadotropin-releasing hormone agonist initiated in the early follicular, midluteal, or late luteal phase in normal cycling women. Fertil Steril. 1995;64:1074–1080. doi: 10.1016/s0015-0282(16)57963-1. [DOI] [PubMed] [Google Scholar]
  • 63.Karande V, Morris R, Rinehart J, Miller C, Rao R, Gleicher N. Limited success using the “flare” protocol in poor responders in cycles with low basal follicle-stimulating hormone levels during in vitro fertilization. Fertil Steril. 1997;67:900–903. doi: 10.1016/s0015-0282(97)81403-3. [DOI] [PubMed] [Google Scholar]
  • 64.Laufer N, Simon A, Hurwitz A, Glatstein IZ. In vitro fertilization. In: Seibel MM, editor. Infertility: A Comprehensive Text. 2nd ed. Stamford, CT: Appleton & Lange; 1996. pp. 703–749. [Google Scholar]
  • 65.Faber BM, Mayer J, Cox B, Jones D, Toner JP, Oehninger S, Muasher SJ. Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favorable pregnancy results in low responders. Fertil Steril. 1998;69:826–830. doi: 10.1016/s0015-0282(98)00040-5. [DOI] [PubMed] [Google Scholar]
  • 66.Scott RT, Navot D. Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization. Fertil Steril. 1994;61:880–885. doi: 10.1016/s0015-0282(16)56700-4. [DOI] [PubMed] [Google Scholar]
  • 67.Feldberg D, Fahri J, Ashkenazi J, Dicker D, Shalev J, Ben-Rafael Z. Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels. Fertil Steril. 1994;62:343–346. doi: 10.1016/s0015-0282(16)56889-7. [DOI] [PubMed] [Google Scholar]
  • 68.Surrey ES, Joann B, Hill DM, Ramsey J, Surrey MW. Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization. Fertil Steril. 1998;69:419–424. doi: 10.1016/s0015-0282(97)00575-x. [DOI] [PubMed] [Google Scholar]
  • 69.Schoolcraft W, Schlenker T, Gee M, Stevens J, Wagley L. Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol. Fertil Steril. 1997;67:93–97. doi: 10.1016/s0015-0282(97)81862-6. [DOI] [PubMed] [Google Scholar]
  • 70.Owen EJ, West C, Mason BA, Jacobs HS. Co-treatment with growth hormone of sub-optimal responders in IVF-ET. Hum Reprod. 1991;6:524–528. doi: 10.1093/oxfordjournals.humrep.a137372. [DOI] [PubMed] [Google Scholar]
  • 71.Homburg R. Growth hormone and fertility-Clinical studies. Horm Res. 1996;45:81–85. doi: 10.1159/000184764. [DOI] [PubMed] [Google Scholar]
  • 72.Volpe A, Coukos G, Barreca A, Artini PG, Ginuto F, Giordano G, Genazzani AR. Ovarian response to combined growth hormone-gonadotropin treatment in patients resistant to induction of superovulation. Gynecol Endocrinol. 1989;3:125–133. doi: 10.3109/09513598909152459. [DOI] [PubMed] [Google Scholar]
  • 73.Bergh C, Hillensjo T, Wikland M, Nilsson L, Borg G, Hamberger L. Adjuvant growth hormone treatment during in vitro fertilization: A randomized, placebo-controlled study. Fertil Steril. 1994;62:113–120. [PubMed] [Google Scholar]
  • 74.Hughes SM, Huang ZH, Morris ID, Matson PL, Buck P, Lieberman BA. A double-blind cross-over study to evaluate the effect of human biosynthetic growth hormone on ovarian stimulation in previous poor responders to in vitro fertilization. Hum Reprod. 1994;9:13–18. doi: 10.1093/oxfordjournals.humrep.a138301. [DOI] [PubMed] [Google Scholar]
  • 75.Suikkari AM, MacLachlan V, Koistinen R, Seppala M, Healy DL. Double-blind placebo controlled study: human biosynthetic growth hormone for assisted reproductive technology. Fertil Steril. 1996;65:800–805. doi: 10.1016/s0015-0282(16)58217-x. [DOI] [PubMed] [Google Scholar]
  • 76.Busacca M, Fusi FM, Brigante C, Bonzi V, Gonfiantini C, Vignali M, Ferrari A. Use of growth hormone-releasing factor in ovulation induction in poor responders. J Reprod Med. 1996;41:699–703. [PubMed] [Google Scholar]
  • 77.Bider D, Blankstein J, Levron J, Tur-Kaspa I. Gonadotropins and glucocorticoid therapy for “low responders”-A controlled study. J Assist Reprod Genet. 1997;14:328–331. doi: 10.1007/BF02765836. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Gonen Y, Jacobson W, Casper RF. Gonadotropin suppression with oral contraceptives before in vitro fertilization. Fertil Steril. 1990;53:282–287. doi: 10.1016/s0015-0282(16)53282-8. [DOI] [PubMed] [Google Scholar]
  • 79.Fisch B, Royburt M, Pinkas H, Avrech OM, Goldman GA, Bar J, Tadir Y, Ovadia J. Augmentation of low ovarian response to superovulation before in vitro fertilization following priming with contraceptive pills. Isr J Med Sci. 1996;32:1172–1176. [PubMed] [Google Scholar]
  • 80.Lindheim SR, Barad DH, Witt B, Ditkoff E, Sauer MV. Short-term gonadotropin suppression with oral contraceptives benefits poor responders prior to controlled ovarian hyperstimulation. J Assist Reprod Genet. 1996;13:745–747. doi: 10.1007/BF02066431. [DOI] [PubMed] [Google Scholar]
  • 81.Lindheim SR, Vidali A, Ditkoff E, Sauer MV, Zinger M. Poor responders to ovarian hyperstimulation may benefit from an attempt at natural-cycle oocyte retrieval. J Assist Reprod Genet. 1997;14:174–177. doi: 10.1007/BF02766136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Scholtes M, Zeilmaker G. A prospective randomized study of embryo transfer results after 3 or 5 days of embryo culture in in vitro fertilization. Fertil Steril. 1996;65:1245–1248. doi: 10.1016/s0015-0282(16)58349-6. [DOI] [PubMed] [Google Scholar]
  • 83.Gardner DK, Vella P, Lane M, Wagley L, Schlenker T, Schoolcraft WB. Culture and transfer of human blastocysts increases implantation rates and reduces the need for multiple embryo transfers. Fertil Steril. 1998;69:84–88. doi: 10.1016/s0015-0282(97)00438-x. [DOI] [PubMed] [Google Scholar]
  • 84.Cohen J, Inge KL, Suzmann M, Wiker SR, Wright G. Video-cinematography of fresh and cryopreserved embryos: A retro-spective analysis of embryonic morphology and implantation. Fertil Steril. 1989;51:820–827. doi: 10.1016/s0015-0282(16)60673-8. [DOI] [PubMed] [Google Scholar]
  • 85.Schoolcraft WB, Schlenker T, Gee M, Jones GS, Jones HW., Jr Assisted hatching in the treatment of poor prognosis in vitro fertilization candidates. Fertil Steril. 1994;62:551–554. doi: 10.1016/s0015-0282(16)56944-1. [DOI] [PubMed] [Google Scholar]
  • 86.Stein A, Rufas O, Amit S, Avrech O, Pinkas H, Ovadia J, Fisch B. Assisted hatching by partial zona dissection of human pre-embryos in patients with recurrent implantation failure after in vitro fertilization. Fertil Steril. 1995;63:838–841. doi: 10.1016/s0015-0282(16)57490-1. [DOI] [PubMed] [Google Scholar]
  • 87.Magli MC, Gianaroli L, Ferraretti AP, Fortini D, Aicardi G, Montanaro N. Rescue of implantation potential in embryos with poor prognosis by assisted zona hatching. Hum Reprod. 1998;13:1331–1335. doi: 10.1093/humrep/13.5.1331. [DOI] [PubMed] [Google Scholar]
  • 88.Hellebaut S, De Sutter P, Dozortsev D, Onghena A, Qian C, Dhont M. Does assisted hatching improve implantation rates after in vitro fertilization or intracytoplasmic sperm injection in all patients? A prospective randomized study. J Assist Reprod Genet. 1996;13:19–22. doi: 10.1007/BF02068864. [DOI] [PubMed] [Google Scholar]
  • 89.Tucker MJ, Morton PC, Wright G, Ingargiola PE, Sweitzer CI, Elsner CW, Mitchell-Leef DE, Massey JB. Enhancement of outcome from intracytoplasmic sperm injection: Does coculture or assisted hatching improve implantation rates? Hum Reprod. 1996;11:2434–2437. doi: 10.1093/oxfordjournals.humrep.a019131. [DOI] [PubMed] [Google Scholar]
  • 90.Lanzendorf SE, Nechrini F, Mayer JF, Oehninger S, Muasher SJ. A prospective, randomized, double-blind study for the evaluation of assisted hatching in patients with advanced maternal age. Hum Reprod. 1998;13:409–413. doi: 10.1093/humrep/13.2.409. [DOI] [PubMed] [Google Scholar]
  • 91.Moreno C, Ruiz A, Simon C, Pellicer A, Remohi J. Intracy-toplasmic sperm injection as a routine indication in low responder patients. Hum Reprod. 1998;13:2126–2129. doi: 10.1093/humrep/13.8.2126. [DOI] [PubMed] [Google Scholar]
  • 92.Palermo GD, Cohen J, Rosenwaks Z. Intracytoplasmic sperm injection: A powerful tool to overcome fertilization failure. Fertil Steril. 1996;65:899–908. doi: 10.1016/s0015-0282(16)58257-0. [DOI] [PubMed] [Google Scholar]
  • 93.Wiemer KE, Cohen J, Tucker MJ, Godke RA. The application of co-culture in assisted reproduction: 10 years of experience with human embryos. Hum Reprod. 1998;13:226–238. doi: 10.1093/humrep/13.suppl_4.226. [DOI] [PubMed] [Google Scholar]
  • 94.Cohen J, Scott R, Alikani M, Schimmel T, Munne S, Levron J, Wu L, Brenner C, Warner C, Willadsen S. Ooplasmic transfer in mature human oocytes. Mol Hum Reprod. 1998;4:269–280. doi: 10.1093/molehr/4.3.269. [DOI] [PubMed] [Google Scholar]
  • 95.Keefe DL, Niven-Fairchild T, Powell S, Buradagunta S. Mitochondrial deoxyribonucleic acid deletions in oocytes and reproductive aging in women. Fertil Steril. 1995;64:577–583. [PubMed] [Google Scholar]
  • 96.Schmidt-Sarosi C. Infertility in the older woman. Clin Obstet Gynecol. 1998;41:940–950. doi: 10.1097/00003081-199812000-00020. [DOI] [PubMed] [Google Scholar]
  • 97.Cha KY, Koo JJ, Choi DH, Han SY, Yoon TK. Pregnancy after in vitro fertilization of human follicular oocytes collected from nonstimulated cycles, their culture in vitro and their transfer in a donor oocyte program. Fertil Steril. 1991;55:109–113. doi: 10.1016/s0015-0282(16)54068-0. [DOI] [PubMed] [Google Scholar]
  • 98.Trounson AO, Wood C, Kausche A. In vitro maturation and the fertilization and developmental competence of oocytes recovered from untreated polycystic ovarian patients. Fertil Steril. 1994;62:353–362. doi: 10.1016/s0015-0282(16)56891-5. [DOI] [PubMed] [Google Scholar]
  • 99.Russell JB: Immature oocyte retrieval combined with in-vitro oocyte maturation. Hum Reprod 1998 (suppl. 3); 13:63–70 [DOI] [PubMed]
  • 100.Van Kooij RJ, Looman CWN, Habbema JDF, Dorland M, Te Velde ER. Age-dependent decrease in embryo implantation rate after in vitro fertilization. Fertil Steril. 1996;66:769–775. doi: 10.1016/s0015-0282(16)58634-8. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Assisted Reproduction and Genetics are provided here courtesy of Springer Science+Business Media, LLC

RESOURCES